 Purinergic P2Y Receptor Antagonists
"Purinergic P2Y Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that bind to and block the stimulation of PURINERGIC P2Y RECEPTORS. Included under this heading are antagonists for specific P2Y receptor subtypes.
| Descriptor ID |
D058921
|
| MeSH Number(s) |
D27.505.519.625.725.400.200.200 D27.505.696.577.725.400.200.200
|
| Concept/Terms |
Adenosine Diphosphate Receptor Antagonists- Adenosine Diphosphate Receptor Antagonists
- ADP Receptor Blockers
- Blockers, ADP Receptor
- Receptor Blockers, ADP
- ADP Receptor Antagonists
- Antagonists, ADP Receptor
- Receptor Antagonists, ADP
|
Below are MeSH descriptors whose meaning is more general than "Purinergic P2Y Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Purinergic P2Y Receptor Antagonists".
This graph shows the total number of publications written about "Purinergic P2Y Receptor Antagonists" by people in UAMS Profiles by year, and whether "Purinergic P2Y Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 1 | 0 | 1 | | 2021 | 1 | 1 | 2 | | 2019 | 1 | 0 | 1 | | 2018 | 2 | 0 | 2 | | 2017 | 1 | 0 | 1 | | 2016 | 2 | 0 | 2 | | 2014 | 2 | 0 | 2 | | 2013 | 1 | 0 | 1 | | 2012 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Purinergic P2Y Receptor Antagonists" by people in Profiles over the past ten years.
-
Jain N, Martin BC, Dai J, Phadnis MA, Al-Hindi L, Shireman TI, Hedayati SS, Rasu RS, Mehta JL. Age Modifies Intracranial and Gastrointestinal Bleeding Risk from P2Y12 Inhibitors in Patients Receiving Dialysis. Kidney360. 2022 08 25; 3(8):1374-1383.
-
Jain N, Phadnis MA, Martin BC, Mehta JL. Potent Antiplatelet Therapy May Reduce Death from Sepsis in Patients on Chronic Dialysis. Am J Cardiol. 2022 01 01; 162:209-211.
-
Balanescu DV, Aziz MK, Donisan T, Palaskas N, Lopez-Mattei J, Hassan S, Kim P, Song J, Ntim W, Cilingiroglu M, Marmagkiolis K, Iliescu C. Cancer treatment resumption in patients with new-generation drug-eluting stents. Coron Artery Dis. 2021 Jun 01; 32(4):295-301.
-
Abo-Aly M, George B, Shokri E, Chelvarajan L, El-Helw M, Smyth SS, Abdel-Latif A, Ziada K. Cangrelor in addition to standard therapy reduces cardiac damage and inflammatory markers in patients with ST-segment elevation myocardial infarction. J Thromb Thrombolysis. 2021 Oct; 52(3):934-940.
-
Jain N, Hunt SL, Cui H, Phadnis MA, Mahnken JD, Shireman TI, Dai J, Mehta JL, Rasu RS. Trends for and Clinical Factors Associated with Choice of Oral P2Y12 Inhibitors for Patients on Chronic Dialysis. Cardiovasc Drugs Ther. 2019 10; 33(5):511-521.
-
Yang X, Leesar MA, Ahmed H, Lendel V, Rodriguez G, Mutlu D, Cawich I, Prasad A, Oglesby M, Marmagkiolis K, Phillips NE, Jouke D, Michalek J, Liu Q, Milner T, McElroy A, Hoyt T, Feldman MD, Cilingiroglu M. Impact of ticagrelor and aspirin versus clopidogrel and aspirin in symptomatic patients with peripheral arterial disease: Thrombus burden assessed by optical coherence tomography. Cardiovasc Revasc Med. 2018 10; 19(7 Pt A):778-784.
-
Singh M, Raghavan D, Williams JS, Martin BC, Hudson TJ, Owen RR, Jain N. Prevalence of Chronic Kidney Disease, Thrombotic Cardiovascular Events, and Use of Oral P2Y12 Inhibitors among Veterans. Am J Nephrol. 2018; 47(2):67-71.
-
Hernandez-Suarez DF, Scott SA, Tomey MI, Melin K, Lopez-Candales A, Buckley CE, Duconge J. Clinical determinants of clopidogrel responsiveness in a heterogeneous cohort of Puerto Rican Hispanics. Ther Adv Cardiovasc Dis. 2017 Sep; 11(9):235-241.
-
Brice AE, Hernandez GA, Sanchez M, Haynick M, Mendoza CE. In-stent thrombosis when switching ticagrelor to clopidogrel after percutaneous coronary intervention. Platelets. 2017 May; 28(3):305-309.
-
Jain N, Reilly RF. Oral P2Y12 Receptor Inhibitors in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions: Current?Knowledge and Future Directions. Semin Dial. 2016 09; 29(5):374-81.
-
Sardar P, Nairooz R, Chatterjee S, Mushiyev S, Pekler G, Visco F. Cangrelor for patients undergoing percutaneous coronary intervention: evidence from a meta-analysis of randomized trials. J Thromb Thrombolysis. 2014 Jul; 38(1):1-10.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|